| Literature DB >> 19411764 |
Michael P Cancro1, David P D'Cruz, Munther A Khamashta.
Abstract
SLE, a chronic, multisystem autoimmune disorder with a broad range of symptoms, involves defective B cell selection and elimination of self-reactive B cells. B lymphocyte stimulator (BLyS), a soluble ligand of the TNF cytokine family, is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. High levels of BLyS may relax B cell selection and contribute to autoantibody production, exacerbating the SLE disease state. This review discusses the mechanism of BLyS action on B cells, its role in SLE, and specific targeting of BLyS in the treatment of SLE.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19411764 PMCID: PMC2673851 DOI: 10.1172/JCI38010
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808